Cardiomyocyte Regeneration: A Consensus Statement

Thomas Eschenhagen, Roberto Bolli, Thomas Braun, Loren J. Field, Bernd K. Fleischmann, Jonas Frisén, Mauro Giacca, Joshua Hare, Steven Houser, Richard T. Lee, Eduardo Marbán, James F. Martin, Jeffery D. Molkentin, Charles E. Murry, Paul R. Riley, Pilar Ruiz-Lozano, Hesham A. Sadek, Mark A. Sussman, Joseph A. Hill

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Cell therapy is an exciting option for repairing the injured heart, one that has attracted considerable interest over the past 15 years. Consensus exists that the injection/infusion or tissue-based implantation of various cell types may exert therapeutic effects,1–3 and there is general agreement that additional molecular, translational, and clinical studies are required to define the optimal cell source, method of delivery, and underlying mechanism(s) of action.One of the remaining questions in this field pertains to cardiomyocyte turnover under normal and diseased conditions and its contribution to the beneficial effects of cell therapy. Although results published in the literature have not been consistent, we believe that the time is ripe to formulate a consensus for many of the pertinent questions.It is important to emphasize that the focus of this consensus statement is on cardiomyocyte renewal; it is not on cell therapy in general. Although we touch on some aspects of therapeutic strategies based on delivery of exogenous cells, our intent here is to define areas of agreement and areas requiring further elucidation related to the regenerative potential of the myocardium itself.We have included references to the scientific literature throughout the document. Although it is impossible for us to include all publications in this expansive field, representative studies that corroborate statements herein have been cited.

Original languageEnglish (US)
JournalCirculation
DOIs
StateAccepted/In press - Jul 7 2017

Fingerprint

Cell- and Tissue-Based Therapy
Cardiac Myocytes
Regeneration
Literature
Therapeutic Uses
Publications
Myocardium
Injections
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Eschenhagen, T., Bolli, R., Braun, T., Field, L. J., Fleischmann, B. K., Frisén, J., ... Hill, J. A. (Accepted/In press). Cardiomyocyte Regeneration: A Consensus Statement. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.117.029343

Cardiomyocyte Regeneration : A Consensus Statement. / Eschenhagen, Thomas; Bolli, Roberto; Braun, Thomas; Field, Loren J.; Fleischmann, Bernd K.; Frisén, Jonas; Giacca, Mauro; Hare, Joshua; Houser, Steven; Lee, Richard T.; Marbán, Eduardo; Martin, James F.; Molkentin, Jeffery D.; Murry, Charles E.; Riley, Paul R.; Ruiz-Lozano, Pilar; Sadek, Hesham A.; Sussman, Mark A.; Hill, Joseph A.

In: Circulation, 07.07.2017.

Research output: Contribution to journalArticle

Eschenhagen, T, Bolli, R, Braun, T, Field, LJ, Fleischmann, BK, Frisén, J, Giacca, M, Hare, J, Houser, S, Lee, RT, Marbán, E, Martin, JF, Molkentin, JD, Murry, CE, Riley, PR, Ruiz-Lozano, P, Sadek, HA, Sussman, MA & Hill, JA 2017, 'Cardiomyocyte Regeneration: A Consensus Statement', Circulation. https://doi.org/10.1161/CIRCULATIONAHA.117.029343
Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisén J et al. Cardiomyocyte Regeneration: A Consensus Statement. Circulation. 2017 Jul 7. https://doi.org/10.1161/CIRCULATIONAHA.117.029343
Eschenhagen, Thomas ; Bolli, Roberto ; Braun, Thomas ; Field, Loren J. ; Fleischmann, Bernd K. ; Frisén, Jonas ; Giacca, Mauro ; Hare, Joshua ; Houser, Steven ; Lee, Richard T. ; Marbán, Eduardo ; Martin, James F. ; Molkentin, Jeffery D. ; Murry, Charles E. ; Riley, Paul R. ; Ruiz-Lozano, Pilar ; Sadek, Hesham A. ; Sussman, Mark A. ; Hill, Joseph A. / Cardiomyocyte Regeneration : A Consensus Statement. In: Circulation. 2017.
@article{2ad7e80bea5e4bae9cc4c4a53fb916a9,
title = "Cardiomyocyte Regeneration: A Consensus Statement",
abstract = "Cell therapy is an exciting option for repairing the injured heart, one that has attracted considerable interest over the past 15 years. Consensus exists that the injection/infusion or tissue-based implantation of various cell types may exert therapeutic effects,1–3 and there is general agreement that additional molecular, translational, and clinical studies are required to define the optimal cell source, method of delivery, and underlying mechanism(s) of action.One of the remaining questions in this field pertains to cardiomyocyte turnover under normal and diseased conditions and its contribution to the beneficial effects of cell therapy. Although results published in the literature have not been consistent, we believe that the time is ripe to formulate a consensus for many of the pertinent questions.It is important to emphasize that the focus of this consensus statement is on cardiomyocyte renewal; it is not on cell therapy in general. Although we touch on some aspects of therapeutic strategies based on delivery of exogenous cells, our intent here is to define areas of agreement and areas requiring further elucidation related to the regenerative potential of the myocardium itself.We have included references to the scientific literature throughout the document. Although it is impossible for us to include all publications in this expansive field, representative studies that corroborate statements herein have been cited.",
author = "Thomas Eschenhagen and Roberto Bolli and Thomas Braun and Field, {Loren J.} and Fleischmann, {Bernd K.} and Jonas Fris{\'e}n and Mauro Giacca and Joshua Hare and Steven Houser and Lee, {Richard T.} and Eduardo Marb{\'a}n and Martin, {James F.} and Molkentin, {Jeffery D.} and Murry, {Charles E.} and Riley, {Paul R.} and Pilar Ruiz-Lozano and Sadek, {Hesham A.} and Sussman, {Mark A.} and Hill, {Joseph A.}",
year = "2017",
month = "7",
day = "7",
doi = "10.1161/CIRCULATIONAHA.117.029343",
language = "English (US)",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Cardiomyocyte Regeneration

T2 - A Consensus Statement

AU - Eschenhagen, Thomas

AU - Bolli, Roberto

AU - Braun, Thomas

AU - Field, Loren J.

AU - Fleischmann, Bernd K.

AU - Frisén, Jonas

AU - Giacca, Mauro

AU - Hare, Joshua

AU - Houser, Steven

AU - Lee, Richard T.

AU - Marbán, Eduardo

AU - Martin, James F.

AU - Molkentin, Jeffery D.

AU - Murry, Charles E.

AU - Riley, Paul R.

AU - Ruiz-Lozano, Pilar

AU - Sadek, Hesham A.

AU - Sussman, Mark A.

AU - Hill, Joseph A.

PY - 2017/7/7

Y1 - 2017/7/7

N2 - Cell therapy is an exciting option for repairing the injured heart, one that has attracted considerable interest over the past 15 years. Consensus exists that the injection/infusion or tissue-based implantation of various cell types may exert therapeutic effects,1–3 and there is general agreement that additional molecular, translational, and clinical studies are required to define the optimal cell source, method of delivery, and underlying mechanism(s) of action.One of the remaining questions in this field pertains to cardiomyocyte turnover under normal and diseased conditions and its contribution to the beneficial effects of cell therapy. Although results published in the literature have not been consistent, we believe that the time is ripe to formulate a consensus for many of the pertinent questions.It is important to emphasize that the focus of this consensus statement is on cardiomyocyte renewal; it is not on cell therapy in general. Although we touch on some aspects of therapeutic strategies based on delivery of exogenous cells, our intent here is to define areas of agreement and areas requiring further elucidation related to the regenerative potential of the myocardium itself.We have included references to the scientific literature throughout the document. Although it is impossible for us to include all publications in this expansive field, representative studies that corroborate statements herein have been cited.

AB - Cell therapy is an exciting option for repairing the injured heart, one that has attracted considerable interest over the past 15 years. Consensus exists that the injection/infusion or tissue-based implantation of various cell types may exert therapeutic effects,1–3 and there is general agreement that additional molecular, translational, and clinical studies are required to define the optimal cell source, method of delivery, and underlying mechanism(s) of action.One of the remaining questions in this field pertains to cardiomyocyte turnover under normal and diseased conditions and its contribution to the beneficial effects of cell therapy. Although results published in the literature have not been consistent, we believe that the time is ripe to formulate a consensus for many of the pertinent questions.It is important to emphasize that the focus of this consensus statement is on cardiomyocyte renewal; it is not on cell therapy in general. Although we touch on some aspects of therapeutic strategies based on delivery of exogenous cells, our intent here is to define areas of agreement and areas requiring further elucidation related to the regenerative potential of the myocardium itself.We have included references to the scientific literature throughout the document. Although it is impossible for us to include all publications in this expansive field, representative studies that corroborate statements herein have been cited.

UR - http://www.scopus.com/inward/record.url?scp=85022216010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022216010&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.117.029343

DO - 10.1161/CIRCULATIONAHA.117.029343

M3 - Article

C2 - 28684531

AN - SCOPUS:85022216010

JO - Circulation

JF - Circulation

SN - 0009-7322

ER -